{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-072633","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-06-11T12:10:25+00:00","discovered_at":"2026-06-11T12:15:02.335478+00:00","generated_at":"2026-06-11T12:15:56.535902+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Theriva Biologics announces VCN-01 Phase 1 HNSCC data showing median OS up to 17.3 months","bullets":["Median OS 10.3-17.3 months across three arms in heavily pre-treated, immunotherapy-refractory HNSCC patients.","Median PFS 1.6-3.7 months; best PFS (3.7 mo) in sequential low-dose VCN-01 arm (Arm II LD).","Biomarker data confirms VCN-01 mechanism: increased PH20, viral replication, CD8+ T cell infiltration, PD-L1 upregulation.","Results published online in Clinical Cancer Research; trial NCT03799744 enrolled 20 patients.","Data suggest VCN-01 can resensitize refractory tumors to checkpoint inhibitor durvalumab."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-072633","json":"https://secwatch.observer/filing/0001104659-26-072633.json","markdown":"https://secwatch.observer/filing/0001104659-26-072633.md","text":"https://secwatch.observer/filing/0001104659-26-072633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926072633/0001104659-26-072633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926072633/tm2617564d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:15:56.535902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}